Literature DB >> 11890477

Recognition of adverse and nonadverse effects in toxicity studies.

Richard W Lewis1, Richard Billington, Eric Debryune, Armin Gamer, B Lang, Francis Carpanini.   

Abstract

One of the most important quantitative outputs from toxicity studies is identification of the highest exposure level (dose or concentration) that does not cause treatment related effects that could be considered relevant to human health risk assessment. A review of regulatory and other scientific literature and of current practices has revealed a lack of consistency in definition and application of frequently used terms such as No Observed Effect Level (NOEL), No Observed Adverse Effect Level (NOAEL), adverse effect, biologically significant effect, or toxicologically significant effect. Moreover, no coherent criteria were found that could be used to guide consistent interpretation of toxicity studies, including the recognition and differentiation between adverse and nonadverse effects. This presentation will address these issues identified first by proposing a standard set of definitions for key terms such as NOEL and NOAEL that are frequently used to describe the overall outcome of a toxicity study. Second, a coherent framework is outlined that can assist the toxicologist in arriving at consistent study interpretation. This structured process involves two main steps. In the first, the toxicologist must decide whether differences from control values are treatment related or if they are chance deviations. In the second step, only those differences judged to be effects are further evaluated in order to discriminate between those that are adverse and those that are not. For each step, criteria are described that can be used to make consistent judgments. In differentiating an effect from a chance finding, consideration is given inter alia to dose response, spurious measurements in individual parameters, the precision of the measurement under evaluation, ranges of natural variation and the overall biological plausibility of the observation. In discriminating between the adverse and the non-adverse effect consideration is given to: whether the effect is an adaptive response, whether it is transient, the magnitude of the effect, its association with effects in other related endpoints, whether it is a precursor to a more significant effect, whether it has an effect on the overall function of the organism. whether it is a specific effect on an organ or organ system or secondary to general toxicity or whether the effect is a predictable consequence of the experimental model. In interpreting complex studies it is recognised that a weight of the evidence approach, combining the criteria outlined here to reach an overall judgment, is the optimal way of applying the process. It is believed that the use of such a scheme will help to improve the consistency of study interpretation that is the foundation of hazard and risk assessment.

Entities:  

Mesh:

Year:  2002        PMID: 11890477     DOI: 10.1080/01926230252824725

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  28 in total

1.  Identification and characterization of adverse effects in 21st century toxicology.

Authors:  Douglas A Keller; Daland R Juberg; Natasha Catlin; William H Farland; Frederick G Hess; Douglas C Wolf; Nancy G Doerrer
Journal:  Toxicol Sci       Date:  2012-01-19       Impact factor: 4.849

2.  QSAR as a random event: a case of NOAEL.

Authors:  Alla P Toropova; Andrey A Toropov; Jovana B Veselinović; Aleksandar M Veselinović
Journal:  Environ Sci Pollut Res Int       Date:  2014-12-19       Impact factor: 4.223

3.  Is It Adverse, Nonadverse, Adaptive, or Artifact?

Authors:  Arun R Pandiri; Roy L Kerlin; Peter C Mann; Nancy E Everds; Alok K Sharma; L Peyton Myers; Thomas J Steinbach
Journal:  Toxicol Pathol       Date:  2016-10-23       Impact factor: 1.902

Review 4.  The determination and interpretation of the therapeutic index in drug development.

Authors:  Patrick Y Muller; Mark N Milton
Journal:  Nat Rev Drug Discov       Date:  2012-08-31       Impact factor: 84.694

5.  Clinical expert panel on monitoring potential lung toxicity of inhaled oligonucleotides: consensus points and recommendations.

Authors:  Eric W Alton; Homer A Boushey; Holger Garn; Francis H Green; Michael Hodges; Richard J Martin; Robert D Murdoch; Harald Renz; Stephen B Shrewsbury; Rosanne Seguin; Graham Johnson; Joel D Parry; Jeff Tepper; Paolo Renzi; Joy Cavagnaro; Nicolay Ferrari
Journal:  Nucleic Acid Ther       Date:  2012-07-18       Impact factor: 5.486

6.  Toxicity testing in the 21st century: using the new toxicity testing paradigm to create a taxonomy of adverse effects.

Authors:  Kim Boekelheide; Sarah N Campion
Journal:  Toxicol Sci       Date:  2009-12-21       Impact factor: 4.849

7.  Identifying diverse metal oxide nanomaterials with lethal effects on embryonic zebrafish using machine learning.

Authors:  Richard Liam Marchese Robinson; Haralambos Sarimveis; Philip Doganis; Xiaodong Jia; Marianna Kotzabasaki; Christiana Gousiadou; Stacey Lynn Harper; Terry Wilkins
Journal:  Beilstein J Nanotechnol       Date:  2021-11-29       Impact factor: 3.649

8.  Toxicity Evaluation of the Naphthalen-2-yl 3,5-Dinitrobenzoate: A Drug Candidate for Alzheimer Disease.

Authors:  Fareeha Anwar; Uzma Saleem; Atta-Ur Rehman; Bashir Ahmad; Matheus Froeyen; Muhammad Usman Mirza; Lee Yean Kee; Iskandar Abdullah; Sarfraz Ahmad
Journal:  Front Pharmacol       Date:  2021-05-10       Impact factor: 5.810

9.  Toxicity assessment and analgesic activity investigation of aqueous acetone extracts of Sida acuta Burn f . and Sida cordifolia L. (Malvaceae), medicinal plants of Burkina Faso.

Authors:  Kiessoun Konaté; Imaël Henri Nestor Bassolé; Adama Hilou; Raïssa R R Aworet-Samseny; Alain Souza; Nicolas Barro; Mamoudou H Dicko; Jacques Y Datté; Bertrand M'Batchi
Journal:  BMC Complement Altern Med       Date:  2012-08-11       Impact factor: 3.659

10.  Safety of Direct Intraparenchymal AAVrh.10-Mediated Central Nervous System Gene Therapy for Metachromatic Leukodystrophy.

Authors:  Jonathan B Rosenberg; Alvin Chen; Bishnu P De; Jonathan P Dyke; Douglas J Ballon; Sebastien Monette; Rodolfo J Ricart Arbona; Stephen M Kaminsky; Ronald G Crystal; Dolan Sondhi
Journal:  Hum Gene Ther       Date:  2021-03-30       Impact factor: 4.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.